SCHEMBL3741672

SCHEMBL3741672

Cc1ccc(N(c2ccc(C)cc2)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
SRD5A2 P31213 3/20 0.65
TP53 P04637 1/20 0.52
TSHR P16473 1/20 0.52
CES2 O00748 2/20 0.50
CES1 P23141 2/20 0.50
LMNA P02545 2/20 0.50
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
NPC1 O15118 2/20 0.48
POLB P06746 1/20 0.48
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
AKR1C3 P42330 1/20 0.46
PKM P14618 2/20 0.45
HTT P42858 2/20 0.45
ATM Q13315 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8973613 1.00 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
SCHEMBL7909102 0.94 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
SCHEMBL2029621 0.89 TSHR (0.67) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
SCHEMBL17040204 0.89 TSHR (0.67) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
SCHEMBL22972761 0.89 TSHR (0.67) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
Terephthalic Acid SCHEMBL526449 0.86 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
4-Methylbenzoic Acid SCHEMBL1331178 0.86 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
Terephthalic Acid SCHEMBL15994097 0.86 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
4-Methylbenzoic Acid SCHEMBL11366477 0.86 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR
4-Methylbenzoic Acid SCHEMBL93638 0.86 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2SRD5A2TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090621-A1 SYSTEMS, DEVICES, AND METHODS FOR SEPARATION OF METALS FROM WASTE, SCRAP, AND POST-CONSUMER PRODUCTS SUNCHEM INC. (US) 2026-04-30 WO claimed
US-20090123860-A1 Triaryl amines such as N,N'-diphenyl-N,N'-bis(3-hydroxyphenyl) [1,1'-biphenyl]-4, 4'-diamineas charge control agents imparting excellent triboelectric charging characteristics to a toner particle comprising a latex, a pigment, and an optional wax; emulsion aggregation toners; xerography; resolution XEROX CORPORATION 2009-05-14 US claimed
WO-2026090621-A1 SYSTEMS, DEVICES, AND METHODS FOR SEPARATION OF METALS FROM WASTE, SCRAP, AND POST-CONSUMER PRODUCTS SUNCHEM INC. (US) 2026-04-30 WO disclosed
US-20250074925-A1 RARE EARTH COMPLEX SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) 2025-03-06 US disclosed
EP-4365180-A1 RARE EARTH COMPLEX Tosoh Corporation (JP) 2024-05-08 EP disclosed
CN-117616032-A Rare earth complex 东曹株式会社 2024-02-27 CN disclosed
WO-2023282236-A1 RARE EARTH COMPLEX 東ソー株式会社 2023-01-12 WO disclosed
US-9704612-B2 Composition of silver-conjugated compound composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-11 US disclosed
US-9704612-B2 Composition of silver-conjugated compound composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-11 US disclosed
US-9536633-B2 Metallic composite and composition thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-01-03 US disclosed
US-9412487-B2 Silver-(conjugated compound) composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-09 US disclosed
US-20120168693-A1 SILVER-(CONJUGATED COMPOUND) COMPOSITE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-05 US disclosed
US-20120168693-A1 SILVER-(CONJUGATED COMPOUND) COMPOSITE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-05 US disclosed
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-09 US disclosed
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-09 US disclosed
US-7833684-B2 Triaryl amines such as N,N'-diphenyl-N,N'-bis(3-hydroxyphenyl) [1,1'-biphenyl]-4, 4'-diamineas charge control agents imparting excellent triboelectric charging characteristics to a toner particle comprising a latex, a pigment, and an optional wax; emulsion aggregation toners; xerography; resolution XEROX CORPORATION (US) 2010-11-16 US disclosed
US-20090123860-A1 Triaryl amines such as N,N'-diphenyl-N,N'-bis(3-hydroxyphenyl) [1,1'-biphenyl]-4, 4'-diamineas charge control agents imparting excellent triboelectric charging characteristics to a toner particle comprising a latex, a pigment, and an optional wax; emulsion aggregation toners; xerography; resolution XEROX CORPORATION 2009-05-14 US disclosed
EP-1246016-B1 Electrophotographic element comprising an insulating charge transport layer EASTMAN KODAK CO (US) 2006-05-24 EP disclosed
US-6517984-B1 Silsesquioxane compositions containing tertiary arylamines for hole transport HEIDELBERGER DRUCKMASCHINEN AG (DE) 2003-02-11 US disclosed
EP-1246016-A2 Electrophotographic element comprising charge transport layer containing silsesquioxane compositions containing teritiary arylaines for hole transport Heidelberger Druckmaschinen Aktiengesellschaft (DE) 2002-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF CDH1, EPCAM, CD4 ALDH1A1 932/4885SMN1; SMN2 2087/4885SRD5A2 2103/4885
US-20250074925-A1 RARE EARTH COMPLEX L1CAM, CHRM1, NPM1 ALDH1A1 2286/4885SMN1; SMN2 3862/4885SRD5A2 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.